A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major

Blood

Volumn 128, Issue 12, 2016, Pages 1555-1561

  Fernandes, Juliano L ^a   Loggetto, Sandra R ^b   Veríssimo, Monica P A ^c   Fertrin, Kleber Y ^d   Baldanzi, Giorgio R ^e   Fioravante, Luciana A B ^a   Tan, Doralice M ^f   Higa, Tatiana ^g   Mashima, Denise A ^h   Piga, Antonio ⁱ   Coelho, Otavio R ^d   Costa, Fernando F ^d   Saad, Sara T ^d  

^a Jose Michel Kalaf Research Institute   (Brazil)

^b Departamento de Hematologia   (Brazil)

^c Centro Infantil Dr Domingos A Boldrini   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e Centro de Hematologia e Hemoterapia Do Paraná HEMEPAR   (Brazil)

^f Marilia Medical School   (Brazil)

^g STATE UNIVERSITY OF MARINGÁ   (Brazil)

^h STATE UNIVERSITY OF LONDRINA   (Brazil)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; PLACEBO; VASODILATOR AGENT;

ADD ON THERAPY; ADOLESCENT; ADULT; ALLERGIC REACTION; ANKLE EDEMA; ARTICLE; BRADYCARDIA; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; FEMALE; HUMAN; HYPOTENSION; IRON BLOOD LEVEL; IRON OVERLOAD; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA MAJOR; TREATMENT DURATION; BETA-THALASSEMIA; CARDIAC MUSCLE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROGNOSIS; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMLODIPINE; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84988697996     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-06-721183     Document Type: Article

References (33)

1. Aydinok Y, Porter JB, Piga A, et al. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol. 2015;95(3):244-253.
2. Carpenter JP, Roughton M, Pennell DJ; Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2∗ cardiovascular magnetic resonance in β-thalassemia major. Haematologica. 2013;98(9):1368-1374.
3. Pennell DJ, Udelson JE, Arai AE, et al; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association [published correction appears in Circulation 2013;128(3):e203]. Circulation. 2013;128(3):281-308.
4. Kirk P, Roughton M, Porter JB, et al. Cardiac T2∗ magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
5. Pennell DJ, Porter JB, Piga A, et al; CORDELIA study investigators. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014;123(10):1447-1454.
6. Pepe A, Meloni A, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson. 2013;15:1.
7. Porter JB, Wood J, Olivieri N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson. 2013;15:38.
8. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2∗ over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48-54.
9. Viprakasit V, Gattermann N, Lee JW, et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus. 2013;11(1):108-122.
10. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2∗ cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-355.
11. Porter JB, Garbowski M. The pathophysiology of transfusional iron overload. Hematol Oncol Clin North Am. 2014;28(4):683-701, vi. [vi.].
12. Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl). 2006;84(5):349-364.
13. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9(9):1187-1194.
14. Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol. 2012;88(6):535-548.
15. Ludwiczek S, Theurl I, Muckenthaler MU, et al. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med. 2007;13(4):448-454.
16. Fernandes JL, Sampaio EF, Fertrin K, et al. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am J Med. 2013;126(9):834-837.
17. He T, Gatehouse PD, Kirk P, et al. Black-blood T2∗ technique for myocardial iron measurement in thalassemia. J Magn Reson Imaging. 2007;25(6):1205-1209.
18. Wacker CM, Hartlep AW, Pfleger S, Schad LR, Ertl G, Bauer WR. Susceptibility-sensitive magnetic resonance imaging detects human myocardium supplied by a stenotic coronary artery without a contrast agent. J Am Coll Cardiol. 2003;41(5):834-840.
19. Positano V, Pepe A, Santarelli MF, et al. Standardized T2∗ map of normal human heart in vivo to correct T2∗ segmental artefacts. NMR Biomed. 2007;20(6):578-590.
20. Carpenter JP, He T, Kirk P, et al. On T2∗ magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519-1528.
21. Garbowski MW, Carpenter JP, Smith G, et al. Biopsy-based calibration of T2∗ magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16:40.
22. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364-2371.
23. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176-186.
24. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447-1457.
25. Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol. 2000;15(3-4):302-316.
26. Tsushima RG, Wickenden AD, Bouchard RA, Oudit GY, Liu PP, Backx PH. Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ Res. 1999;84(11):1302-1309.
27. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992;22(1):22-31.
28. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
29. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884.
30. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12.
31. Voskaridou E, Ladis V, Kattamis A, et al; Greek Haemoglobinopathies Study Group. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol. 2012;91(9):1451-1458.
32. Alam MH, Auger D, Smith GC, et al. T1 at 1.5T and 3T compared with conventional T2∗ at 1.5T for cardiac siderosis. J Cardiovasc Magn Reson. 2015;17:102.
33. Ang AL, Tzoulis P, Prescott E, Davis BA, Barnard M, Shah FT. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with b thalassemia major. Eur J Haematol. 2014;92(3):229-236.